Abstract 3158
Background
Continued smoking after a HNC diagnosis is associated with poorer outcomes. Proximity to tobacco retail outlets is negatively associated with cessation in non-cancer patients (pts) but this has not been evaluated in cancer survivors. We evaluated the impact of tobacco retail access on cessation in HNC pts.
Methods
HNC pts (Princess Margaret Cancer Centre, Toronto, Canada) completed questionnaires at diagnosis and follow up (median 26 months apart) evaluating changes in tobacco use. Validated tobacco retail location data were obtained from Ontario Ministry of Health and pt home addresses were geocoded using ArcGIS 10.6.1, which calculated walking time/distance to nearest vendor and vendor density within 250 meters (m) and 500m from pts. Multivariable logistic regression and Cox proportional hazard models evaluated the impact of vendor availability on cessation and time to quitting after diagnosis respectively, adjusted for significant clinico-demographic and tobacco covariates.
Results
141/450 HNC pts smoked at diagnosis; quit rate after diagnosis was 48%. Mean distance and walking time to a vendor was 1.2 km (range 0-10) and 14 min (range 0-116). On average, there was 1 vendor (range 0-19) within 250m and 3 vendors (range 0-19) within 500m from pts; 33% and 56% of pts lived within 250m and 500m from at least one vendor, respectively. Greater distance (aOR 1.27 per 1000m [95% CI 1.01-1.59] p = 0.04) and increased walking time (aOR 1.02 per min [1.00-1.04] p = 0.04) to a vendor were associated with a higher quit rate at one year. Living near more vendors within 500m was associated with an increasing dose effect on reducing cessation rates at 1 year (aOR 0.90 per vendor [0.82-0.99] p = 0.03). Greater distance (aHR 1.18 per 1000m [1.01-1.38] p = 0.04) and increased walking time (aHR 1.01 per min [1.00-1.03] p = 0.04) to a vendor were also associated with quitting at any time. Living near more vendors within 500m had a trend towards reducing quit rates at any time (aHR 0.94 per vendor [0.88-1.00] p = 0.07).
Conclusions
Close proximity to tobacco retail outlets is associated with reduced cessation rates for HNC survivors. Reducing density of tobacco vendors is a cessation strategy that can positively impact HNC pt outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5683 - Prevention of chemoradiation-related mucositis in patients with head and neck cancer using dexamethasone-based mouthwash: A phase II randomized double-blind, placebo-controlled study
Presenter: Naiyarat Prasongsook
Session: Poster Display session 1
Resources:
Abstract
5437 - Salivary cytokines and oral mucosa cells apoptosis in patients during hematopoietic cell transplantation: possible relationship with oral mucositis
Presenter: Luciana Corrêa
Session: Poster Display session 1
Resources:
Abstract
1483 - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401
Presenter: Toshihide Yokoyama
Session: Poster Display session 1
Resources:
Abstract
2047 - Taste and smell alterations (TSAs) in patients (pts) with stage II-III colon cancer (CC): a pilot within the PROTECT study
Presenter: Jeroen Derksen
Session: Poster Display session 1
Resources:
Abstract
5984 - Clinical characteristics are associated with acupuncture treatment response for xerostomia in cancer patients
Presenter: Wenli Liu
Session: Poster Display session 1
Resources:
Abstract
2845 - Psychosocial Distress of Adolescent and Young Adults with Cancer at Diagnosis: A Case-Matched Retrospective Cohort of 2045 Patients in British Columbia.
Presenter: Alannah Smrke
Session: Poster Display session 1
Resources:
Abstract
724 - Accuracy of distress thermometer to measure cancer-related mood disorders in Chinese patients with cancer
Presenter: Sudip Thapa
Session: Poster Display session 1
Resources:
Abstract
2357 - Modalities of biosimilar filgrastim use in clinical practice in >1000 patients receiving chemotherapy regimens with a rest period of ≤14 days: the TOPAZE study
Presenter: Jean Marc Phelip
Session: Poster Display session 1
Resources:
Abstract
1426 - The Effect of Increasing Doses of Pegfilgrastim (Peg) on Thrombocytopenia (T) in Breast Cancer (BC) Patients (pts) Receiving Taxotere (Doc), Doxorubicin, Cyclophosphamide (TAC) and Plinabulin (Plin)
Presenter: Douglas Blayney
Session: Poster Display session 1
Resources:
Abstract
712 - The use of intravenous ferric carboxymaltose without erythropoiesis-stimulating agents in the treatment of anemia in cancer patients undergoing chemotherapy with or without radiotherapy
Presenter: Hikmat Abdel-Razeq
Session: Poster Display session 1
Resources:
Abstract